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Abstract: More than 70 years ago, Prof. Pierre Masson, a renowned French-Canadian pathologist 
(1880–1959), advised us that “No classification is more difficult to establish than that of thyroid carcinomas…
Of all cancers, they teach, perhaps, the greatest lessons of humility to histopathologists.” Almost 70 years later, the 
recent evidence-based reclassification of the non-invasive encapsulated follicular variant of papillary thyroid 
carcinoma (FVPTC) as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 
has demonstrated that this problematic is still ongoing. For about 30 years, it was wrongly assumed that 
the encapsulated FVPTC behaved and spread like its classical counterpart and, therefore, that it should be 
treated likewise. As such, the renaming of a malignant entity as a nonmalignant (albeit not benign) neoplasm 
has contributed to optimizing patient care by deescalating treatment and follow-up for an indolent neoplasm, 
decreasing medical expense and complications possibly caused by further treatment including radioactive 
iodine, and reassuring patients with this diagnosis. At the same time, NIFTP has significant implications not 
only for the practice of thyroid cytopathology but also for surgical pathology and for molecular tests, creating 
significant new challenges. NIFTP has rigorous histopathologic diagnostic criteria, including papillary-
like nuclear features, and submission of the entire tumor capsule and content is required to exclude both 
invasion and presence of papillary structures. Cytologically, because of the morphological overlap with other 
follicular neoplasms and with papillary thyroid carcinoma (PTC), most NIFTP are diagnosed into one of the 
indeterminate Bethesda categories (III–V) and can be adequately triaged for surgery. From a molecular view, 
NIFTP are most often characterized by RAS-type mutations, similar to other follicular-patterned lesions, 
and molecular testing can be helpful to suggest NIFTP preoperatively. In this review, we focus on the impact 
of NIFTP on the diagnosis of thyroid nodules. 
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Introduction
In one of his most popular books entitled “Human Tumors” (1), 
the renowned French-Canadian pathologist Prof. Pierre 
Masson [1880–1959], recognized as a pioneer in his field 
and as “the father of histopathology teaching in Canada”, 
advised us that “No classification is more difficult to establish 
than that of thyroid carcinomas… Of all cancers, they teach, 
perhaps, the greatest lessons of humility to histopathologists.” In 
2016, almost 70 years later, the reclassification of a group 
of low-risk tumors known as non-invasive encapsulated 
follicular variant of papillary thyroid carcinoma (FVPTC) 
into a new entity, non-invasive follicular thyroid neoplasm 
with papillary-like nuclear features (NIFTP) (2,3), 
demonstrates the veracity of this statement. As such, the 
renaming of a malignant entity as a nonmalignant (albeit 
not benign) neoplasm has contributed to optimizing patient 
care by deescalating treatment and follow-up for an indolent 
neoplasm, decreasing medical expense and complications 
possibly caused by further treatment including radioactive 
iodine, and reassuring patients with this diagnosis. At the 
same time, NIFTP has significant implications not only for 
the practice of thyroid cytopathology but also for surgical 
pathology and for molecular tests, creating significant new 
challenges (4,5). Within 2.5 years, there have been more 
than 150 publications with a keyword of NIFTP according 
to a PubMed literature search on November 1st, 2018 
(https://www.ncbi.nlm.nih.gov/pubmed/?term=niftp). 
These publications cover many aspects on this new tumor 
entity, including cytological and histological diagnosis, 
ultrasound (US) features, molecular genotyping, clinical 
management and long-term outcome of NIFTP patients. 
In this review, we focus on the impact of NIFTP on the 
diagnosis of thyroid nodules, starting with a case study. 
Case study
A 34-year-old female underwent a thyroid fine needle 
aspiration (FNA) biopsy for a 2.5-cm nodule in the right 
lobe. Cytological evaluation showed moderately cellular 
smears composed of atypical follicular cells arranged 
essentially in microfollicles. The cells had moderate to 
marked nuclear atypia including enlargement, nuclear 
membrane irregularities with several grooves, and chromatin 
pallor (Figure 1A). However, no nuclear pseudoinclusions, 
nor papillary structure or psammoma body were identified. 
The FNA was diagnosed as: “Malignant, papillary thyroid 
carcinoma (Bethesda diagnostic category VI)” with the following 
explanatory note: “a follicular variant of papillary thyroid 
carcinoma (FVPTC) is favored; with the recent reclassification 
of a subset of indolent FVPTC as non-invasive follicular thyroid 
neoplasm with papillary-like nuclear features (NIFTP), the 
positive predictive value of the malignant category for thyroid 
FNA is expected to drop from 99% to 94–96%.” Thus, a small 
proportion of cases diagnosed as malignant by FNA may prove 
to be NIFTP upon histologic examination.” Subsequently, the 
patient underwent a repeat FNA for molecular testing 
with ThyGenX®, which assesses the most common genetic 
alterations across eight genes associated with papillary 
thyroid carcinoma (PTC) and follicular thyroid carcinoma 
(FTC), including TERT promoter mutation. PAX8/PPARƔ 
rearrangement was found in isolation, which was highly 
suggestive of a low-risk follicular neoplasm (FN), mainly 
FVPTC or NIFTP and less commonly FTC of follicular 
adenoma (6). A right hemithyroidectomy with central 
compartment lymph node dissection was performed, and 
the histological examination of the thyroid nodule showed 
an invasive encapsulated FVPTC (EFVPTC) with both 
vascular and capsular invasion (Figure 1B,C,D). The tumor 
was limited to the thyroid gland without lymph node 
metastasis (pT2 pN0). No adjuvant treatment was given to 
the patient, according to the American Thyroid Association 
(ATA) guidelines 2015 (7) for low-risk thyroid carcinomas.
What is NIFTP?
The incidence of thyroid cancer diagnoses has tripled over 
the past 30 years, and PTC has accounted entirely for this 
increase (8). In contrast, the mortality rate has remained 
very low, indicating the indolent clinical behavior of the vast 
majority of thyroid cancers which were identified during 
that time (8). The term overdiagnosis has been applied to 
this concept of finding subclinical disease that is not likely 
to progress. In fact, the increased incidence of PTC is 
related to increased detection of small tumors including 
microcarcinomas (<1 cm) and a shift in pathological 
diagnostic criteria over time with the increased recognition 
and diagnosis of FVPTC. Specifically, the prevalence of 
the EFVPTC has increased and this entity accounted for 
10–25% of all newly diagnosed thyroid cancers in Europe 
& North America a few years ago (9,10). Prior to the 
introduction of the NIFTP nomenclature, all encapsulated 
follicular pattern tumors with nuclear features of PTC, even 
without invasive growth, were categorized as malignant 
tumors (i.e., non-invasive EFVPTC) (9,10). Since the 
nuclear features of PTC are subjective, the diagnostic 
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reproducibility of EFVPTC, even among experts, was 
historically extremely poor (9-11). For about 30 years, it was 
wrongly assumed that EFVPTC behaved and spread like its 
classical counterpart and, therefore, that it should be treated 
likewise. As an example, in the first edition of the Bethesda 
System for Reporting Thyroid Cytopathology (TBSRTC) 
from 2009 (12), it was stated that “FVPTC behaves clinically 
in a manner indistinguishable from conventional PTC”. 
Therefore, a major challenge of cytopathologists at that 
time and before the era of NIFTP, was to diagnose this 
entity as malignant or at least suspicious for malignancy 
(SFM), in order to limit the rate of false negative 
diagnoses. During the last decade, however, it was found 
that FVPTC is a heterogeneous group of tumors and that 
the clinical behavior and molecular features of the non-
invasive EFVPTC, the most common subtype of FVPTC, 
resemble those of the follicular adenoma/carcinoma group 
of tumors (RAS-like) rather than the classic PTC group of 
tumors (BRAF-like) (2,9-10). It was found that EFVPTC 
is indolent when there is no vascular or capsular invasion, 
akin to follicular adenoma. On the other hand, encapsulated 
invasive FVPTC (with capsular and/or vascular invasion) 
is essentially identical to FTC in its behavior, molecular 
profile and pathological criteria, except for the nuclear 
changes of PTC. Therefore, similar to EFVPTC and 
NIFTP, some authors have suggested to rename this entity 
as well (e.g., FTC with nuclear atypia?), if additional studies 
show that they are indeed identical to FTC (13). The 
NIFTP nomenclature was subsequently introduced in 2016 
by an international multidisciplinary group of endocrine 
pathology experts, on the basis of a retrospective study 
of a large number of cases of non-invasive and infiltrative 
EFVPTCs (2). The consensus term NIFTP that they 
proposed refers to a non-invasive neoplasm of thyroid 
follicular cells with a follicular growth pattern and nuclear 
features of PTC. By removing the word “carcinoma”, the 
A B
C D
Figure 1 On cytology (A) and corresponding histology (B), the tumor cells are organized in microfollicles and show several nuclear features 
of PTC, including chromatin pallor, nuclear enlargement and nuclear membrane irregularities including a few grooves. Note that nuclear 
pseudoinclusions are absent. The evaluation of the tumor capsule on histology reveals evidence of both capsular (C) and vascular (D) 
invasion, two histologic features that rule-out the diagnosis of NIFTP. The final diagnosis in this case was an invasive encapsulated FVPTC. 
PTC, papillary thyroid carcinoma; NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; FVPTC, follicular 
variant of papillary thyroid carcinoma. Magnification: A and B, 400×; C, 100×; D, 200×.
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main goal of this new nomenclature is to optimize patient 
care by deescalating treatment and follow-up, decrease 
medical expense and complications possibly caused by 
further treatment including completion thyroidectomy 
and radioactive iodine, while at the same time reassuring 
patients with this diagnosis who would no longer have the 
psychological stigma of cancer and its collateral damages 
(2,3,5). Importantly, NIFTP is considered a neoplasm with 
extremely low malignant potential and is best considered 
a premalignant lesion (borderline), rather than a purely 
benign or a frankly malignant lesion. The diagnosis of 
NIFTP is based on a combination of very strict inclusion 
and exclusion histologic criteria (2,5,14-16), namely on the 
finding of an encapsulated or sharply demarcated nodule 
with complete lack of invasive characteristics and cells with 
a follicular growth pattern showing nuclear features of 
PTC, without any well-formed papillary structures (even 
if up to 1% of papillae was initially accepted), psammoma 
bodies, significant solid growth (>30%), high mitotic 
rate, or tumor necrosis. The presence of other growth 
patterns indicative of aggressive variants of PTC, such as 
tall cell, columnar cell, and hobnail variants, also excludes 
the diagnosis of NIFTP. Because a definitive diagnosis of 
NIFTP can be made only after exclusion of invasion and 
the other features mentioned above, a complete histologic 
examination of the tumor capsule and/or tumor interface is 
required. Some NIFTP have a thick capsule, while a subset 
has a thin or incomplete capsule, and another subset have 
no capsule entirely but are well circumscribed with a sharp 
interface with adjacent thyroid parenchyma. Unlike classical 
PTC and most other variants of PTC, the nuclear atypia 
is typically more subtle in NIFTP, and range from diffuse 
in distribution to patchy (so called “sprinkling sign”) and 
multifocal. Some of the exclusion criteria for NIFTP, such 
as no papillae, no psammoma bodies, and no tumor necrosis, 
also suggest that the entire tumor should be submitted 
along with the capsular area (5). In most recent updates, 
the diagnostic criteria have been slightly revised, which 
now require no well-formed papillae and no BRAFV600E 
mutation, RET/PTC rearrangement or high-risk mutations 
such as TERT promoter (see below) (14-16). The new 
term NIFTP has been recommended for use by many 
professional societies including ATA (17), and is included as 
a new chapter on borderline tumors (i.e., ICD-O behavior 
code 1: neither benign nor malignant) of follicular cell 
origin in the latest “WHO Classification of Tumours of 
Endocrine Organs” published in 2017 (18). Since NIFTP 
is a new entity, it is expected that the diagnostic criteria will 
be further refined when more data becomes available in the 
future.
How common is NIFTP? 
A recent meta-analysis found that NIFTP is averaging 9.1% 
of all PTCs worldwide (19), which is lower that what was 
initially suggested (2). However, the prevalence of NIFTP 
varies significantly among different areas, countries and 
institutions around the world, ranging from <1% up to 
28% of all thyroid cancer diagnosis in retrospective studies 
[thoroughly reviewed by Bychkov et al. (19)]. Especially, the 
incidence of NIFTP in the Asian population is much lower 
than that in the non-Asian series. Such difference could be 
attributed several factors including: (I) various histological 
diagnostic criteria and thresholds for follicular-patterned 
thyroid lesions, which diagnostic reproducibility even 
among experts has been shown to be relatively poor; (II) 
geographic factors (e.g., iodine content) and ethnic (genetic 
traits) background which may influence the type, molecular 
mechanisms and mutation profile of PTCs. For example, 
the high prevalence of BRAFV600E mutation in Korean 
and Japanese patients is associated with a predominance 
of classic PTC over FVPTC; (III) variations and biases 
in the retrospective studies, including different ways to 
identify and to count NIFTP (e.g., based on the number 
of all thyroid malignancies or only PTC cases, with or 
without incidental microcarcinomas in the total number of 
cancers); and (IV) different approaches in the management 
of cytologically indeterminate thyroid nodules between 
Western and Asian countries (see below). 
How does NIFTP impact cytology?
The reclassification of the non-invasive EFVPTC 
(“malignant”) as NIFTP (“nonmalignant”) has significant 
implications, for the diagnosis of thyroid nodules at the 
cytological, histological, ultrasonographic and molecular 
level (4,5), especially in areas of the world where the 
prevalence of NIFTP is high such as North America, 
Brazil and some countries in Europe. In contrast, in Asia 
where the proportion of non-invasive EFVPTC is very low, 
ranging between 0.3–0.4% in China up to 4.7% in Taiwan, 
the impact of NIFTP for the diagnosis of thyroid nodules 
will be minimal (19,20). 
The  Bethesda  Sys tem for  Report ing  Thyro id 
Cytopathology (TBSRTC) (12,21) provides a standardized 
framework for the classification of thyroid FNA specimens 
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based on cytomorphologic criteria, and has been endorsed 
by the latest 2015 ATA guidelines for the management of 
patients with thyroid nodules (7). Each of the 6 interpretive 
categories of TBSRTC is associated with an approximate 
risk of malignancy (ROM), which clinicians use to guide 
management of patients with a thyroid nodule (Table 1). 
The most significant impact of NIFTP reclassification 
is a decrease in the implied ROM, particularly for cases 
classified into 3 of the so-called “indeterminate” diagnostic 
categories of TBSRTC where the vast majority of NIFPT 
cases (90%) are clustered (22-26): (I) category III—
atypia of undetermined significance/follicular lesion of 
undetermined significance (AUS/FLUS); (II) category IV—
FN/suspicious for a FN (FN/SFN); and (III) category V—
SFM (Table 1). Recent studies suggest that the decrease 
in ROM as a result of NIFTP will be most significant (up 
to 50%) for thyroid FNA specimens classified as SFM 
(22-26). In contrast, there is no significant change in the 
ROM for FNA specimens classified as benign, and only 
a small decrease (3–4% on average based upon a limited 
number of retrospective studies) for the malignant category. 
As an example, Faquin et al. (22) reported a series of 6,943 
thyroid FNA specimens pooled from five institutions and 
found that 173 were diagnosed as NIFTP in the surgical 
resection specimens out of 756 malignant cases (23%). 
The preoperative FNA cytological diagnoses for these 
173 NIFTPs were characterized as: nondiagnostic (1%), 
benign (9%), AUS/FLUS (31%), FN/SFN (27%), SFM 
(24%), and malignant (9%). When NIFTPs are considered 
nonmalignant lesions, the ROM is decreased by 1.4%, 
3.5%, 13.6%, 15.1%, 23.4%, and 3.3%, in each Bethesda 
category (I to VI), respectively. Nonetheless, there are 
arguments against associating NIFTP’s new nonmalignant 
status with benignity and with revised ROMs. Although 
NIFTP is considered an indolent neoplasm with very low 
malignant potential, surgery (i.e., lobectomy) is considered 
the standard of care (5,17) and is necessary to establish the 
diagnosis of NIFTP definitively. Given this, it may not 
make sense to cluster NIFTPs with histologically benign 
nodules, for which nonsurgical follow-up is generally 
Table 1 The Bethesda System for Reporting Thyroid Cytopathology: implied risk of malignancy and recommended clinical management in 2009 
(before NIFTP) and in 2018 (after NIFTP)
Diagnostic category
Risk of 
malignancy  
(1st edition 2009)
Risk of malignancy 
without NIFTP  
(2nd edition 2018)
Risk of malignancy 
with NIFTP  
(2nd edition 2018)
Usual management 
(1st edition 2009)
Usual management 
(2nd edition 2018)
Non-diagnostic or 
unsatisfactory
Not assessed 5–10% No significant 
changes
Repeat FNA with 
ultrasound guidance
No significant 
changes
Benign 0–3% No significant 
changes
No significant 
changes
Clinical and 
sonographic follow-
up
No significant 
changes
Atypia of undetermined 
significance or follicular lesion 
of undetermined significance
5–15% 10–30% 6–18% Repeat FNA with 
ultrasound guidance
Repeat FNA, 
molecular testing, 
or lobectomy*
Follicular neoplasm or 
suspicious for a follicular 
neoplasm
15–30% 25–40% 10–40% Lobectomy Molecular testing, 
lobectomy**
Suspicious for malignancy 60–75% 50–75% 45–60% Near-total 
thyroidectomy or 
lobectomy
Near-total 
thyroidectomy or 
lobectomy***
Malignant 97–99% No significant 
changes
94–96% Near-total 
thyroidectomy
Near-total 
thyroidectomy or 
lobectomy***
*, after consideration of clinical and sonographic features, investigations such as repeat FNA or molecular testing may be used to 
supplement malignancy risk assessment instead of proceeding directly with a strategy of either surveillance or diagnostic surgery (5); **, after 
consideration of clinical and sonographic features, molecular testing may be used to supplement malignancy risk assessment data instead of 
proceeding directly with surgery (5); ***, molecular testing may be used if the result is expected to alter the extent of surgery (5). Adapted with 
permission from (21). FNA, fine needle aspiration; NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features.
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accepted in contrast to NIFTP (7,17). Acknowledging 
these conflicting perspectives, the second edition of 
TBSRTC (21) offers two updated versions of the ROMs: 
one that considers NIFTP as benign and another one that 
considers NIFTP as malignant (Table 1). ROMs that include 
NIFTP may be more meaningful clinically in countries 
where they are operated. In contrast, ROM without NIFTP 
may further support conservative management in some 
countries where borderline tumors are preferably followed-
up clinically and radiologically (27) (see below). In the end, 
this binary (“black and white”) benign versus malignant 
histopathologic separation, although useful for statistical 
analysis and management purposes, may not be accurate in 
the sense that it does not reflect the progressive nature of 
thyroid neoplasia, which now includes a borderline category 
(“the gray zone”).
Can we diagnose NIFTP preoperatively?
I t  i s  current ly  not  poss ib le  to  d iagnose  NIFTP 
preoperatively by a single marker or a single technique (5). 
As exemplified in our case study, a combination of cytologic, 
ultrasonographic and molecular features can suggest the 
possibility of FVPTC or NIFTP or rule out this possibility 
in favor of classic PTC for example, but the definitive 
diagnosis requires complete histologic examination as 
discussed above. The key features of each individual 
preoperative test with regards to NIFTP diagnosis are 
discussed below.
Cytologic features of NIFTP
By definition, NIFTP is a hybrid neoplasm with significant 
cytomorphological overlap with FNs and classic PTC. 
FNAs of NIFTP are characterized by a microfollicular 
architecture along with variably nuclear features of PTC, 
including enlargement, crowding, contour irregularities 
with grooves, and chromatin clearing (5,28-34). In contrast, 
nuclear pseudoinclusions are rare (if any), and papillary 
structures and psammoma bodies should be absent (by 
definition). Additionally, and importantly, the nuclear 
features of NIFTP are generally more subtle than those of 
classical PTC, but more obvious than in benign follicular 
nodules (21,28-34). Because of sampling effects and tumor 
heterogeneity, they can be focal or widespread in the FNA 
specimen. For this reason, most NIFTP are diagnosed 
into one of the indeterminate Bethesda categories: AUS/
FLUS, FN/SFN or SFM (22-26,28-34). As such, FNA can 
be considered as a good screening test for NIFTP since the 
majority of these cases will be triaged for surgery. Similar to 
FTC, the possibility of NIFTP may be raised preoperatively 
on cytology. However, the diagnostic confirmation of 
NIFTP can be made only on the surgical specimen. 
While cytopathologic ability to distinguish NIFTP from 
invasive FVPTC is not possible, cytological features can 
be used to help exclude a diagnosis of NIFTP in favor of a 
classical PTC diagnosis (28-34). In a review of 52 patients, 
Strickland et al. showed that the majority of NIFTPs and 
other follicular lesions such as follicular adenoma can be 
distinguished from classical PTC on cytopathology (29). 
NIFTP cases tended to exhibit a microfollicular growth 
pattern, whereas classical PTC cases tended to demonstrate 
papillae, pseudoinclusions, or psammomatous calcifications. 
Classical PTCs were accurately diagnosed preoperatively 
by cytopathology in 95% of cases. Brandler et al. found 
that NIFTP should be considered when PTC nuclear 
features and microfollicles are present (28). Bizzarro 
et al. found that NIFTP usually lacks pseudoinclusions 
and papillary structures (30). Howitt et al. also found 
statistically significant differences in cytomorphologic 
features between NIFTP and PTC (25); among PTC cases, 
96% demonstrated tumor sheets, 50% had papillae, 79% 
had pseudoinclusions, and microfollicles were seen in only 
4% of cases. In contrast, NIFTP demonstrated tumor 
sheets in 36% of cases, and microfollicles in 55% of cases, 
while papillae or pseudoinclusions were absent from all 
cases. Similarly, Renshaw and Gould. demonstrated that 
both papillae lined by cells with nuclear features of PTC 
and cellular swirls are highly specific for the diagnosis of 
PTC, since neither of them are seen in NIFTP (35). In a 
small subset of cases, however, cytopathologists may not be 
able to favor classical PTC or NIFTP/infiltrative FVPTC 
(IFVPTC). For these cases, US correlation and molecular 
testing may help to determine the best initial surgical 
approach (36,37).
Molecular features of NIFTP
Since molecular testing for indeterminate thyroid nodules is 
addressed in another chapter of this focused issue, we focus 
herein on the molecular features of NIFTP and molecular 
testing in the context of NIFTP. 
The use of molecular testing on FNA material can 
assist in suggesting the diagnosis of NIFTP (5,36,38-43). 
Most cases of NIFTP demonstrate molecular clonal 
alterations which support the concept that NIFTP is 
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a true neoplastic entity despite its indolent behavior 
(Table 2) (2). NIFTPs are primarily associated with 
activating mutations of 1 of the 3 RAS genes (NRAS > 
HRAS >> KRAS), with a frequency of 36–67%. Other driver 
mutations/alterations identified in NIFTP include PAX8-
PARG rearrangement (4–22%), THADA (thyroid adenoma 
associated) fusions (22%), EIF1AX (7%, often coexisting 
with RAS mutation), and occasionally BRAFK601E 
mutations (4%) (2). However, none of the mutations 
present in NIFTPs are pathognomonic of this entity (43). 
Although RAS mutations are the dominant alteration in 
NIFTPs, they are also common in follicular adenomas 
and carcinomas, FVPTC (encapsulated and invasive) 
(Table 2), as well as poorly differentiated and anaplastic 
thyroid cancers. Similarly, PAX8-PPARG is also found in 
FTC and invasive FVPTC (Table 2) (6), as exemplified 
in our case study. The fact that NIFTP, non-invasive 
EFVPTC, and invasive EFVPTC show similar molecular 
profiles suggests a common pathway of progression in 
encapsulated follicular-patterned tumors, with or without 
nuclear features of PTC. Thus, the presence of any of these 
mutation in a preoperative cytological specimen does not 
allow for the definitive diagnosis of NIFTP. In contrast, 
a distinctive aspect of NIFTP lesions is the absence of 
BRAFV600E mutation, TERT promoter mutation, RET/
PTC rearrangement and other mutations/fusions associated 
with classical and tall cell variants of PTC (2,5,38-43). 
These mutations should not be found in appropriately 
diagnosed NIFTPs, and therefore, their presence in a 
preoperative cytological specimen essentially rules out 
NIFTP. Molecular testing has been endorsed by the 2015 
ATA guidelines as an alternative option in managing thyroid 
nodules with an indeterminate diagnosis on FNA (7), in 
particular the AUS and the FN/SFN categories, but it may 
also be considered for SFM and Malignant if the results 
are expected to changes the management (i.e., extent of 
surgery). A number of molecular tests have been studied 
and validated, essentially before the era of NIFTP, and are 
available for clinical usage. The most popular ones in North 
America are the proprietary Thyroseq®, a targeted Next-
Generation Sequencing, and Afirma®, a Gene Expression 
Classifier (42). Unfortunately, these expensive tests are 
currently not available in many other countries. All the 
common mutations and fusions detected in NIFTP can 
Table 2 Mutations in NIFTP and other follicular neoplasms
Mutation/gene fusion Follicular adenoma NIFTP Invasive EFVPTC IFVPTC Follicular carcinoma Classic PTC
BRAF V600E + ++ ++
BRAF K601E + + +
NRAS Q61R/K ++ ++ ++ + ++
HRAS Q61R/K ++ + + + +
KRAS ++ + + + + +
PTEN ++ +
TSHR ++ +
GNAS ++
TERT promoter + +
RET/PTC + ++
PAX8/PPARG + + + ++
THADA fusions + +
ALK fusions + + +
BRAF fusions +
ETV6/NTRK3 + + +
NTRK1/NTRK3 +
+, uncommon; ++, common. NIFTP, non-invasive follicular tumor with papillary-like nuclear features; EFVPTC, encapsulated follicular 
variant of papillary thyroid carcinoma; IFVPTC, infiltrative follicular variant of papillary thyroid carcinoma; PTC, papillary thyroid carcinoma. 
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be captured by Thyroseq®. The introduction of NIFTP 
as a non-malignant tumor changes the performance of 
molecular tests (44). Therefore, the utility, predictive 
value, and reporting of currently available molecular tests 
will need to be reassessed in the era of NIFTP. Early work 
confirms that NIFTP terminology will alter test specificity 
and overall rate of malignancy, essentially by decreasing the 
positive predictive value of the test (44). For this reason, 
Thyroseq® results are now reported as being either positive 
or negative for a mutation, and a probability of cancer 
including its type and aggressiveness is given according to 
the type of alteration, in order to better assist management. 
In contrast to Thyroseq®, Afirma® is less informative since 
it only provides a binary result (benign vs. suspicious) rather 
than a specific genetic alteration (42). Limited studies 
suggest that NIFTP can be detected by Afirma® classifier, 
with most NIFTP being classified as “suspicious”, and 
that it actually represents the most common “carcinoma” 
associated with a suspicious result (42,43).
Ultrasonographic features of NIFTP
US risk stratification of thyroid nodules with indeterminate 
cytology is addressed separately in this focused issue. 
Herein, we briefly review the salient features of NIFTP. 
Yang et al. have reviewed 179 cases and have categorized 
ultrasonography characteristics and cytomorphologic FNA 
features for different FVPTC categories (45). They found 
that the US features of NIFTP and minimally invasive 
EFVPTCs were similar and could not be distinguished 
from each other; both typically exhibited a circumscribed 
oval or round nodule with a hypoechoic rim and a 
hypervascular Doppler signal. In contrast, US features for 
overtly invasive EFVPTC typically showed a round or 
oval nodule with irregular margins and hypervascularity 
on Doppler. US for an invasive FVPTC typically reveals 
at least one of these features: markedly hypoechoic, taller-
than-wide, microcalcifications, or blurred margins with an 
avascular Doppler pattern. US features of NIFTP appear 
to be most often similar to follicular adenoma. Most but 
not all NIFTPs are benign-appearing, round-to-oval, 
circumscribed nodules with a hypoechoic rim, without 
microcalcifications on US. 
Recently, the American College of Radiology (ACR) 
proposed a Thyroid Imaging Reporting and Data System 
(TI-RADS) for thyroid nodules based on ultrasonographic 
features. In the study by Rosario et al. (46), nodules 
corresponding to NIFTP were classified according to 
ACR as TI-RADS 3 in 28.5% of cases, TI-RADS 4 in 
67.8%, and TI-RADS 5 in only 3.5%. In contrast, nodules 
corresponding to cancer were classified as TI-RADS 3 in 
only 2.3% of cases, TI-RADS 4 in 27%, and TI-RADS 5 
in 70.5%. 
Therefore, US features appear to complement cytology 
findings and may help raise pre-operative concern for 
NIFTP in the proper clinical setting, potentially leading to 
a more conservative management approach.
Coming to terms with NIFTP on cytology; the 
revised Bethesda system 2017
In 2017, the NCI published a revision and update on the 
Bethesda system for reporting for thyroid cytopathology (21) 
based mainly on the symposium entitled “The Bethesda 
System for Reporting Thyroid Cytopathology (TBSRTC): 
Past, Present, and Future” held at the October 2016 
International Congress of Cytology in Yokohama, Japan, 
the results of which were published in a joint publication 
summarizing the proposed modifications and updates for 
the second edition from an international panel (47,48). The 
2017 Bethesda System revision was inspired by new data 
and new developments in the field of thyroid pathology 
since 2009, including not only NIFTP terminology (2) 
but also revised guidelines for the management of patients 
with thyroid nodules (7) and the introduction of molecular 
testing as an adjunct to cytopathologic examination.
Since  NIFTP cannot  be  accurate ly  d iagnosed 
preoperatively, the main challenge is how to provide the 
surgeon with reliable and useful information before the 
histological diagnosis in order to optimally guide the initial 
surgical planning, with the main objective of avoiding 
overtreatment for an indolent neoplasm. To this purpose, 
several adjustments were made in order to accommodate 
NIFTP concept on cytology. In TBSRTC 2017 (21), the 
six general diagnostic categories remained unchanged. 
ROMs have been updated based on data since 2010 and 
are calculated in two ways: when NIFTP is not considered 
a malignancy and when NIFTP is still included among 
carcinomas (see above). Molecular testing was incorporated 
as an option for usual management of AUS/FLUS and FN/
SFN nodules. Additionally, the diagnostic criteria for FN/
SFN and malignancy-PTC were slightly modified (49). 
Modified diagnostic criteria
Because of the subsequent overtreatment and potential 
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medico-legal implications, it is highly desirable to exclude 
potential NIFTP cases from the Malignant category, and to 
limit the malignant category to conventional PTC and other 
variants of PTC (21,49,50). The clinical impact of NIFTP 
is not confined to the malignant category, as many patients 
with an SFM cytology diagnosis are also treated with an 
upfront total thyroidectomy, making the drop in ROM for 
the SFM category also important. In a survey conducted in 
2015, prior to the NIFTP reclassification of 2016 and the 
revised more conservative ATA guidelines of 2015, among 
clinically active members of the Endocrine Society, ATA 
and American Association of Clinical Endocrinologists, 
92% of respondents indicated that they performed a total 
thyroidectomy based on a malignant FNA diagnosis, and 
43% reported performing an initial total thyroidectomy if 
the FNA diagnosis is SFM (51).  
It is now suggested in the second edition of TBSRTC 
(21,49) that a definitive diagnosis of PTC (Malignant) 
should be limited to cases that have, in addition to other 
characteristic features, at least one of the following: 
papillary architecture, psammoma bodies, or several nuclear 
pseudoinclusions. An aspirate displaying only microfollicles 
with PTC nuclear features, even when obvious, should 
raise concern for NIFTP. However, it is unlikely that 
NIFTP can be eliminated entirely from the malignant 
category. For example, rare cases of NIFTP have frequent 
pseudoinclusions and, thus, these cases might be categorized 
as malignant on FNA despite more strict criteria. As a 
result, it is important for clinicians and patients to be aware 
that, although the vast majority of nodules with a malignant 
diagnosis on FNA will be a PTC on resection, there is still 
a low rate of false positive results due to some tumors which 
are related to PTC and share their nuclear features such as 
hyalinizing trabecular tumor and now NIFTP. Rather than 
creating a separate diagnostic category to accommodate 
NIFTP, having most NIFTP cases diagnosed in the FN/
SFN category, which was historically designed to identify 
potential FTC, make sense, since the management of these 
neoplasms is similar (47,48).
Explanatory notes with NIFTP in the differential 
diagnosis (“NIFTP note”)
An option initially suggested by Krane et al. (50) which has 
been endorsed by TBSRTC (21,47-49) is to add explanatory 
notes to the cytologic diagnosis about the possibility of 
NIFTP on histologic follow-up. This can be particularly 
useful to support a more conservative clinical management 
as recommended by the latest ATA guidelines for low-risk 
thyroid neoplasms (7,17) (see below).
What is the impact on the management?
Surgical management of cytologically indeterminate 
thyroid nodules is addressed separately in this focused 
issue. Currently, most but not all of the authorities consider 
NIFTP as a surgical disease, which requires resection for 
diagnostic purpose and to prevent possible progression 
to invasive phenotype (5,7,17). As clinical management 
of these tumors is being evaluated by various professional 
societies, further recommendations for managing patients 
with NIFTP and other borderline tumors are expected 
to be issued and incorporated into clinical practice. As 
per current ATA practice guidelines (7,17), the proposed 
reclassification/terminology change is primarily semantic 
in nature. However, the proposed reclassification should 
not be interpreted as indicative of a changed risk profile 
of an inherently low-risk neoplasm, or as supporting a 
nonsurgical approach to these neoplasms, as accurate 
preoperative identification of NIFTP has not yet been 
demonstrated (17). NIFTP lesions nonetheless warrant 
excision by lobectomy to exclude an invasive FVPTC, 
classical PTC, or other thyroid malignancy (5). Once 
the diagnosis of NIFTP is made histologically, however, 
further therapy such as completion thyroidectomy and/
or radioactive iodine therapy may not be warranted and a 
more conservative approach is recommended (17). The full 
impact of NIFTP is yet to be determined but it will further 
encourage an initial lobectomy in many circumstances.
With NIFTP concept and the revised ATA guidelines 
(7,17), the potential role of frozen section (intraoperative 
consultation) to guide the extent of surgery (i.e., total 
thyroidectomy, lymph node dissection) for cases suspicious 
for NIFTP on cytology and for indeterminate thyroid 
cytology in general (Bethesda III–V) needs to be reevaluated 
by prospective studies. Due to limited sampling, a definitive 
diagnosis of NIFTP is not possible during intraoperative 
consultation. Akin to FTC, limited sampling during frozen 
section is also unlikely to identify minimal capsular or 
vascular invasion and to distinguish invasive EFVPTC 
from NIFTP. Also, manipulating/cutting the fresh (unfixed) 
nodule during intraoperative exam can hinder the definitive 
analysis of the tumor capsule and the identification of 
subtle foci of capsular and vascular invasion. In contrast, it 
may be possible to rule out NIFTP by its exclusion criteria 
(e.g., invasion or papillary architecture) and to recognize 
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the invasive FVPTC or classical PTC with predominant 
follicular growth based on their different architectural 
features. However, as for molecular tests, this would be 
useful only if the results are expected to change the extent 
of surgery.
In contrast to this Western approach, the active 
surveillance for indeterminate nodules and NIFTP, largely 
represented in the indeterminate cytologic categories 
which is endorsed by Japanese institutions establishes 
an alternative model to reduce overtreatment of these 
patients (27). According to the Japan Thyroid Association 
clinical guidelines, diagnostic surgery is not indicated for 
patients with FN/SFN nodules when patients have benign 
clinical findings. However, patients with FN/SFN nodules 
are actively monitored until any suspicious clinical and/or 
imaging findings appear (27). 
Limitations and future directions
The NIFTP concept is recent and is still a work in progress. 
The indolent behavior, natural history, optimal treatment 
and follow-up of this disease should be further addressed 
in additional studies, preferably in prospective series of 
patients with long-term follow-up (52,53). Other studies 
will also allow need to address the reproducibility and 
robustness of the diagnostic criteria for NIFTP. 
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